Diabetes Research Focus: Diabetic Mouse Modeling

Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options.

Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). Diabetes can be categorized into three primary forms - type 1, type 2, and gestational diabetes - each with distinct underlying causes. T2DM is characterized by hyperinsulinemia, insulin resistance, and pancreatic beta-cell failure (up to 50% apoptosis). Incretin effects, changes in the colon and its microbiota, immune dysregulation, and inflammation have now emerged as important pathophysiological factors. The mechanisms of microvascular and macrovascular complications caused by hyperglycemia are endothelial dysfunction, advanced glycation end-product formation, hypercoagulable state, increased platelet reactivity, high expression of sodium-glucose cotransporter-2 (SGLT-2), These are all targets for the treatment of diabetes.

With the prevalence of diabetes increasing at an alarming rate, there is a critical need for innovative research solutions to better understand and combat this epidemic. The use of mouse models enables the study of diabetes in a way that closely mirrors the disease in humans, helping to explore disease mechanisms, find biomarkers, and evaluate potential treatments.

Ace Therapeutics provides diverse diabetic mouse models targeting type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM). The T1DM mouse models allow researchers to study the mechanism of type 1 diabetes, identify biomarkers, and test potential therapies. Mouse models for T2DM study is generated by feeding mice a high-fat or high-sugar diet or genetically modifying mice to develop obesity and insulin resistance. These models matter a lot in type 2 diabetes research. Different from T2DM mouse models, GDM mouse models involve feeding mice a high-fat or high-sugar diet during pregnancy or genetically modifying mice to develop impaired glucose tolerance and insulin resistance during pregnancy.

“With the launch of our diabetic mouse models, we are excited to provide researchers with a reliable and versatile platform to advance their understanding of diabetes and develop novel treatments,” said the marketing manager of Ace Therapeutics. “Our models offer a high level of accuracy and reproducibility, allowing for more precise and reliable results in preclinical studies.”

Ace Therapeutics’ mouse models mimic the key characteristics of human diabetes, such as hyperglycemia, insulin resistance, and pancreatic dysfunction, making them invaluable for investigating disease pathology and testing new therapeutics. These mouse models are available for purchase immediately and can be customized to meet specific research needs as well.

About Ace Therapeutics

With a team of experienced researchers and state-of-the-art facilities, Ace Therapeutics strives to accelerate the development of innovative therapies that address unmet medical needs. From early-stage research to translational medicine, Ace Therapeutics offers tailored solutions to facilitate preclinical studies, enabling the transformation of promising concepts into life-changing treatments.